What is Eastgate Biotech Corp?
, a development stage company, develops novel formulations of natural compounds and pharmaceutical products.
ETBI · Verdict
Limited reward · moderate risk
ETBI stands out on volatility and balance sheet, but watch the profitability signal.
Based on 75% data coverage
ETBI · Verdict
Above average
Current ratio 0.00
0% return on equity
Earnings +20.1% CAGR
Model-based scoring. For information only — not financial advice.
, a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 1.06M.
The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.